Skip to main content

Table 1 Patient clinical characteristics (n = 75)

From: Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer

  n %
Age (years)
 Median (range) 65 (40–80)
Sex
 Male 49 65
 Female 26 35
Stage grouping*
 I 12 16
 II 5 7
 III 31 41
 IV 27 36
Histology
 Adenocarcinoma 56 75
 Squamous cell carcinoma 18 24
 Pleomorphic carcinoma 1 1
EGFR status#
 Mutation not found 47 63
 Mutation found 28 37
ALK/ROS1 status
 Rearrangement not found 72 96
 Rearrangement found 3 4
  1. Abbreviations: EGFR = epidermal growth factor receptor; ALK = anaplastic lymphoma kinase; ROS1 = c-ros oncogene 1
  2. * Staging was performed according to the guidelines of the American Joint Committee on Cancer, 8th edition
  3. # EGFR mutation was defined as the presence of an EGFR exon19del or L858R mutation in tumor genomic DNA
  4. † ALK/ROS1 rearrangement was defined as the presence of an ALK or ROS1 rearrangement in tumor genomic DNA